How Does Semaglutide Actually Work? One Molecule, Three Brand Names

What is semaglutide, in plain terms?

Semaglutide is a GLP-1 receptor agonist — a synthetic version of glucagon-like peptide-1, a hormone your gut releases in small amounts after a meal. The natural hormone is nearly identical in structure to semaglutide, but it breaks down within minutes. Semaglutide is engineered to resist that breakdown: it binds to albumin in your blood and is stabilized against the enzyme that would normally clear it, which is why one dose can keep working for roughly a week instead of minutes.

That single molecule is what's inside Ozempic, the newer Ozempic tablet, Wegovy, Rybelsus, and every compounded semaglutide product on the market. The differences between them come down to dose, delivery method, and which FDA approval each one carries — not the underlying chemistry, which is identical across all of them.

What does semaglutide actually do in the body?

Once it's binding to GLP-1 receptors, semaglutide is working on four fronts at roughly the same time:

• Pancreas: prompts insulin release, but only when blood sugar is already elevated — a glucose-dependent effect that's a big part of why it doesn't tend to cause the sugar crashes older diabetes drugs can.
• Liver: lowers how much glucagon, a sugar-raising hormone, reaches the liver — so less stored glucose gets dumped into your blood between meals.
• Stomach: slows gastric emptying in the early hours after eating, which extends the physical sensation of fullness.
• Brain: acts directly on appetite centers in the hypothalamus and brainstem, quieting hunger signals — the effect behind the weight loss almost everyone associates with the name now.

That last effect isn't a separate function bolted onto a diabetes drug — it's the same receptor biology showing up in a different tissue. GLP-1 receptors sit in appetite-regulating parts of the brain as well as the pancreas, which is exactly why a molecule built to manage blood sugar produced weight loss substantial enough to justify its own dedicated brand and trials.

What is semaglutide actually approved to treat — and what isn't it approved for?

Approvals attach to the brand, not the molecule, and they've expanded a lot since 2017. In short: Ozempic covers type 2 diabetes plus cardiovascular and (since January 2025) kidney-disease risk reduction; Wegovy covers chronic weight management plus cardiovascular risk reduction and, since 2025, a liver condition called MASH; the oral versions are approved for diabetes only. The next section breaks down which product carries which approval in more detail.

What none of these brands is approved for: weight loss attached to a diabetes-labeled product, or any use decided by a patient rather than a licensed prescriber working from a documented diagnosis. When Ozempic gets prescribed for weight loss anyway, that's a legal, common, off-label use borrowing its evidence from Wegovy's own trials — not a separate approval Ozempic itself carries.

Ozempic, Wegovy, Rybelsus, compounded — which one is actually "semaglutide"?

All of them, technically — the confusion is that the word describes the molecule, and four different products are built from it. Ozempic is a weekly injection, topping out at 2mg, approved for type 2 diabetes control plus the cardiovascular and kidney-disease risk reduction covered above. Ozempic's full mechanism and approval history goes deeper into that brand specifically. Wegovy is also a weekly injection, dosed higher — up to 2.4mg standard, with a 7.2mg step-up option for people who've plateaued — and carries the weight-management, cardiovascular, and liver-disease approvals; Wegovy's own mechanism guide covers its brand-specific history in full. Rybelsus was the original daily oral tablet, taken on an empty stomach, approved for diabetes only; as of May 2026, Novo Nordisk replaced it in the US with a next-generation oral tablet sold under the Ozempic name itself, effectively retiring the Rybelsus brand domestically while it continues to be sold under that name elsewhere.

Compounded semaglutide is the fourth category, and its legal footing has tightened. The FDA declared the national semaglutide shortage resolved in February 2025, which removed the emergency justification that let compounding pharmacies fill copies of the brand-name drug at scale. Since then, a 503A pharmacy can still compound semaglutide for an individual patient, but generally only when a prescriber documents a clinically meaningful reason the commercial product won't work for that specific person — not simply as a cheaper substitute. Larger 503B outsourcing facilities face an even tighter squeeze: in April 2026 the FDA proposed removing semaglutide from the list of bulk ingredients they're allowed to compound from at all, a proposal still open for comment as of this writing. Compounded semaglutide hasn't disappeared, but "available" and "straightforwardly legal at any dose" are no longer the same thing.

What are the real benefits, beyond the number on the scale?

The same mechanism that suppresses appetite also does measurable work elsewhere in the body, which is easy to lose track of once a drug becomes shorthand for weight loss. Because insulin release only kicks in when blood sugar is already high, semaglutide tends to improve glucose control without the hypoglycemia risk older diabetes medications carry. In dedicated cardiovascular outcomes trials, both Ozempic and Wegovy reduced the rate of heart attack, stroke, and cardiovascular death in people who already had heart disease. Ozempic's 2025 approval added a kidney-protective benefit for people with both diabetes and chronic kidney disease, and Wegovy's 2025 approval recognized a benefit for a serious form of fatty liver disease. None of that erases the weight-loss headline — it just means the biology underneath it is doing more than the headline suggests.

Does perimenopause change how semaglutide works — or why women 40+ end up on it?

The receptor biology itself doesn't shift with reproductive stage; semaglutide binds the same GLP-1 receptors at 46 as it would at 26. What changes is the body it's acting on. Declining, fluctuating estrogen during perimenopause is linked to rising insulin resistance, a shift in fat storage toward the abdomen rather than the hips, and a drop in resting metabolic rate as muscle mass declines — skeletal muscle is a major driver of whole-body insulin sensitivity, so losing it compounds the problem. Those shifts can move someone's blood sugar or weight into a range where a GLP-1 medication becomes clinically relevant for the first time in her 40s, independent of anything she's doing differently. That's a large part of why this conversation starts now for so many women, rather than at twenty-five.

How is semaglutide actually taken, and how soon does it start working?

Delivery depends on which product you're on: Ozempic and Wegovy are once-weekly subcutaneous injections, while the current Ozempic tablet is a daily pill taken on an empty stomach. Every version starts at a low dose and climbs gradually over weeks to months — a titration schedule set by a prescriber, not something to adjust on your own. Appetite is usually the first thing to shift, often within the first couple of weeks as the dose increases; meaningful, sustained change in weight or blood sugar typically takes months, not days. The full semaglutide dosage schedule covers the specific step-by-step numbers for each brand, which don't belong in a mechanism overview like this one.

What's the catch — side effects and the boxed warning?

The most common complaints — nausea, constipation, diarrhea — trace directly back to the same mechanism that's doing the work: slowing digestion. They cluster hardest in the first weeks after each dose increase and typically ease as your body adjusts. The more serious safety concern is a boxed warning, the FDA's strongest label warning, for thyroid C-cell tumors seen in rodent studies; it hasn't been confirmed in humans, but it's serious enough that semaglutide is contraindicated for anyone with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2. That warning is tied to the molecule itself, so it applies identically across Ozempic, Wegovy, the oral tablet, and compounded versions — the brand name doesn't change what's underneath it. Semaglutide's full side-effect picture goes deeper into what's common versus what's actually rare.

How does semaglutide compare to tirzepatide — and is it legitimate to be on?

Tirzepatide — the molecule in Mounjaro and Zepbound — works on the same GLP-1 receptor semaglutide does, plus a second one, GIP, at the same time. That dual action appears to produce a somewhat larger average effect in head-to-head trial data, though the two molecules cause a very similar family of side effects and semaglutide has years more real-world use behind it, with Ozempic on the market since 2017. Neither drug is universally the better choice — it depends on how much a larger average result is worth against cost and your own tolerance. Semaglutide versus tirzepatide breaks that comparison down by price and by profile.

On legitimacy: the FDA-approved forms of semaglutide — Ozempic, the Ozempic tablet, and Wegovy — are backed by nearly a decade of clinical trial and real-world data when prescribed and monitored by a licensed clinician. Compounded semaglutide can be legitimate too, but the legal room for it has narrowed since the shortage was declared resolved, and it's worth knowing which category a given source falls into before you start.